The Vanquish device’s clinical data demonstrated an elimination of MRI visible intermediate risk disease in 91% of patients ...

Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated, or they’re serious enough to require surgery and radiation. Monitoring can cause patients anxiety.

AUA 2017, holep laser, green laser beam, laser, urology, nephrology Men with low-risk PCa who underwent partial gland ablation with vascular-targeted photodynamic therapy were less likely than those ...

IRVINE, Calif. and MIAMI, Aug. 28, 2023 (GLOBE NEWSWIRE) -- CLS Americas, a leading provider of office-based, focal laser ablation systems in the US urology market, and Focalyx® today announced a ...

IRVINE, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS), today announced the clinical study performed in collaboration with Toronto General Hospital, Canada, ...

LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today ...

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO ...

IRVINE, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for ...

IRVINE, Calif. and MIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) -- CLS Americas, a leading provider of office-based, focal laser ablation systems in the US urology market, today announced the full twenty ...

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today ...